Pharmacogenetics of antidepressants: Clinical aspects

Acta Psychiatrica Scandinavica

Volumn 96, Issue SUPPL.391, 1997, Pages 14-21

  Bertilsson, L ^a   Dahl, M L ^a   Tybring, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressants; P450; Pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; FLUOXETINE; MEPHENYTOIN; NEUROLEPTIC AGENT; OMEPRAZOLE; SPARTEINE; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

BLOOD SAMPLING; CONFERENCE PAPER; DEPRESSION; DRUG METABOLISM; GENE MUTATION; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PSYCHOSIS; TREATMENT PLANNING; ADULT; AGED; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; METABOLIC CLEARANCE RATE; PHARMACOEPIDEMIOLOGY; RACE; REVIEW;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; PHARMACOEPIDEMIOLOGY; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; VARIATION (GENETICS);

EID: 0030630527     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb05954.x     Document Type: Article

References (63)

1. HAMMER W, SJOQVIST F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967: 6: 1895-1903.
2. ALEXANDERSON B, EVANS DAP, SJOOVISR F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 1969: 2: 764-768.
3. ALEXANDERSON B, BORGA O urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 1973: 5: 174-180.
4. BERTILSSON L, ALEXANDEKSON B. Stereospecific hydroxyla-tion of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972 4 201-205.
5. DAHL SG. Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 2986: 11: 36-61.
6. BERTILSSON L, DAHL ML. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996: 5: 200-223.
7. INGELMAN-SUNDBERG M, JOHANSSON I. The molecular gene tics of human drug metabolizing cytochrome P450s. In: PACIFICI GM, FRACCHIA GN, ed. Advances in drug metab olism in man, Luxembourg: European Commission, 1995: 543-585.
8. MAHGOUB A, IDLE JR, DRING DG et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977: 2: 584-586.
9. TUCKER GT. SILAS JH, IYUN A0 et al. Polymorphic hydroxylation of debrisoquine in man [letter]. Lancet 1977: 2: 718.
10. EICHELBAUM M, SPANNBRUCKER N, STEINKE B et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979: 16: 183-187.
11. EICHELBAUM M, BERTILSSON L, SAWE J et al. Polymorphic oxidation of sparteine and debrisoquine: related pharma cogenetic entities. Clin Pharmacol Ther 1982: 31: 184-186.
12. STEINER E, BERTILSSON L, SAWE J, BERTLING I, SJOQVIST F. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988: 44: 431-435.
13. EVANS DA, MAHGOUB A, SLOAN TP et al. A family and population study of the genetic polymorphism of debriso quine oxidation in a white British population. J Med Genet 1980: 17: 102-105.
14. BERTILSSON L, LORI YQ, DU YL et al. Pronounced differences between native Chinese and Swedish popula tions in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992: 51: 388-397.
15. BROLY F, GAEDIGK A, HEIM M et al. Debrisoquine/ sparteine hydroxylation genotype and phenotype: ana lysis of common mutations and alleles of CYP2D6 in an European population. DNA Cell Biol 1991: 10: 545-558.
16. DAHL M-L, JOHANSSON I, PORSMYR PALMERTZ M et al. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992: 51: 12-17.
17. KAGIMOTO M, HEIM M, KAGIMOTO K et al. Multiple muta tions of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990: 265: 17209-17214.
18. HEIM M, MEYER UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336: 529-532.
19. BERTILSSON L, DAHL M-L, SJOQVIST F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993: 341: 63.
20. JOHANSSON I, LUNDQVIST E, BERTILSSON L et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90: 11825-11829.
21. DAHL M-L, JOHANSSON I, BERTILSSON L et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274: 516-520.
22. AGUNDEZ JAG, LEDESMA MC, LADERO JM, BENITEZ J. Prevalence of CYP2D6 gene duplication and its repercus sion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57: 265-269.
23. JOHANSSON 1, OSCARSSON M. YUE QY et al. Genetic analysis of the Chinese CYP2D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capa city for debrisoquine hydroxylation. Mol Pharmacol 1994: 46: 452-459.
24. YOKOTA H. TAMURA S, FLIRUYA H et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993: 3: 256-263.
25. KALOW W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991: 12: 102-107.
26. MASIMIREMBWA C, PERSON I, BERTILSSON L, HASLER J, INGELMAN-SUNDBERG M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996: 42: 713-719.
27. AKLILLU E, PERSON I, BERTILSSON L, JOHANSSON I, RODRIGUEZ F, INGELMAN-SUNDBERG I. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated func tional CYP2D6 alleles. J Pharmacol Exp "her 1996: 278: 441-446.
28. BERTILSSON L, EICHELBAUM M, MELLSTROM B et al. Nortriptyline and antipyrine clearance in relation to debri soquine hydroxylation in man. Life Sci 1980 27: 1673-1677.
29. MELLSTROM B, BERTILSSON L, SAWE J et al. E- and Z-10-hydroxylation of nortriptyline; relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981: 30: 189-193.
30. NORDIN C, SIWERS B, BENITEZ J et al. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients - relationship to the debrisoquine metabolic ratio. Br J Clin Pharmacol 1985: 19: 832-835.
31. MELLSTROM B, BERTILSSON L, BIRGERSSON C et al. E- and Z-10-hydroxylation of nortriptyline by human liver micro-somes - methods and characterization. Drug Metab Disp 1983: 11: 115-119.
32. BERTILSSON L, MELLSTROM B, SJOQVIST F et al. Slow hydroxylation of nortriptyline and concomitant poor debri soquine hydroxylation: clinical implication. Lancet 1982: 1: 560-561.
33. SJOQVIST F, BERTILSSON L. Clinical pharmacology of anti-depressant drugs: pharmacogenetics. In: USDIN E, ASBERG M, BERTILSSON L et al., ed. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 359-372.
34. BERTILSSON L, ABERG-WISTEDT A, GUSTAFSSON LL et al. Extremely rapid hydroxylation of debrisoquine; a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985: 7: 478-480.
35. BALANT-GORGIA AE, SCHULTZ P, DAYER P et al. Role of oxidation polymorphism on blood and urine concen trations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 1982: 232: 215-222.
36. MELLSTROM B, SAWE J. BERTILSSON L et al. Amitriptyline metabolism: association with debrisoquine hydroxylation in nonsmokers. Clin Pharmacol Ther 1986: 39: 369-371.
37. BERTILSSON L, ABERG-WISTEDT A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983: 1.5: 388-390.
38. SPINA E, BIRGERSSON C, VON BAHR C et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver micro-somes. Clin Pharmacol Ther 1984: 36: 677-682.
39. SPINA E, STEINER E, ERICSSON 0 et al. Hydroxylation of des methylimipramine: dependence on the debrisoquine hydroxy lation phenotype. Clin Pharmacol Ther 1987: 41: 314-319.
40. DAHL M-L, ISELIUS L, ALM C et al. Polymorphic 2-hydroxylation of desipramine: a population and family study. Eur J Clin Pharmacol 1993: 44: 445-450.
41. BALANT-GORGIA AE, BALANT LP, GENET C et al. Impor tance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986: 31: 449-455.
42. MELLSTROM B, BERTILSSON L, LORI Y-C et al. Amitriptyline metabolism; relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1983: 34: 516-520.
43. SKJELBO E, BROSEN K, HALLAS J et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991: 49: 18-23.
44. COWRRS RT, SU P, BAKER GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 1994: 31: 177-186.
45. DAHL M-L, TVBRING G, ELWIN C-E et al. Stereoselective disposition of rnianserin is related to debrisoquine hydroxy lation polymorphism. Clin Pharmacol Ther 1994: 56: 176-183.
46. FIRKUSNY L, GLEITER H. Maprotiline metabolism appears to cosegregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994: 37: 383-388.
47. CARILLO JA, DAHL M-L, SVENSSON J-0, ALM C, RODRIGUEZ I, BERTILSSON L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6, but also CYP1A2 activity. Clin Pharmacol Ther 1996: 60: 183-190.
48. SINDRUP SH, BROSEN K, GRAM LF et al. The relationship between paroxetine and the sparteine oxidation poly morphism. Clin Pharmacol Ther 1992: 51: 278-287.
49. SINDRUP SH, BROSEN K, HANSEN MGJ et al. Pharmaco-kinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993: 15: 11-17.
50. EICHELBA~JM M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988: 37: 93-96.
51. DAVIS R, WILDE MI. Mirtazapine. A review of its pharma cology and therapeutic potential in the management of major depression. CNS Drugs 1996: 5: 389-402.
52. DAHL M-L, VOORTMAN G, ALM C et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997: 13: 37-46.
53. SINDRUP SH, BROSEN K, GRAM LF et al. The relationship between paroxetine and the sparteine oxidation poly morphism. Clin Pharmacol Ther 1992: 51: 278-287.
54. SPIGSET 0, CARLEBORG L, HEDENMALM K, DAHLUVIST R. Effect of cigarette smoking on fluvoxamine pharma-cokinetics in humans. Clin Pharmacol Ther 1995: 58: 399-403.
55. JERLING M, LINDSTROM L, BONDESSON U, BERTILSSON L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a thera peutic drug monitoring service. Ther Drug Monit 1994: 16: 368-374.
56. BERTILSSON L, CARRILLO JA, DAHL M-L et al. Clozapine disposition covaries with CYPlA2 activity determined by a caffeine test. Br J Clin Pharmacol 1994: 38: 471-473.
57. BR0SEN K, SKJELBO E, RASM~JSSEN BB, POULSEN HE, LOFT S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993: 45: 1211-1214.
58. BKGSEN K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993: 71: 1002-1009.
59. GRAM LF, GUENTERR TW, GRANGE s et a\. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYPlA2; a panel study. Clin Pharmacol Ther 1995: 57: 670-677.
60. SELLERS EM, BALL SE, CHELJNG SW et al. Inhibition by venlafaxine (VF) and other SHT uptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharma-cology, 13-17 December 1993, Honolulu, 163.
61. CREWE HR, LENNARD MS, TUCKER GT et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992: 34: 262-265.
62. GRAM LF, FREDRICSON-OVER@ K. Drug interaction: inhibi tory effect of neuroleptics on metabolism of tricyclic antidepressants in man. BMJ 1972: 1: 463-465.
63. JERLING M, BERTILSSON L, SJOUVIST F. The use of thera peutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortripty-line. Ther Drug Monit 1994: 16: 1-12.